JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 131 filers reported holding JOUNCE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 5.36 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $383,978 | -96.0% | 345,926 | -91.6% | 0.01% | -96.0% |
| Q3 2022 | $9,581,000 | -19.9% | 4,094,488 | +3.7% | 0.35% | -24.1% |
| Q2 2022 | $11,967,000 | -55.6% | 3,949,668 | -0.6% | 0.46% | -54.7% |
| Q1 2022 | $26,976,000 | -18.7% | 3,972,868 | 0.0% | 1.01% | -10.6% |
| Q4 2021 | $33,173,000 | +16.0% | 3,972,868 | +3.2% | 1.13% | +34.2% |
| Q3 2021 | $28,597,000 | +28.9% | 3,848,822 | +18.0% | 0.84% | +21.0% |
| Q2 2021 | $22,187,000 | -33.8% | 3,262,833 | 0.0% | 0.70% | -32.1% |
| Q1 2021 | $33,509,000 | -22.1% | 3,262,833 | +69.6% | 1.02% | +17.0% |
| Q1 2018 | $42,994,000 | +61.6% | 1,923,651 | -7.8% | 0.87% | +38.5% |
| Q4 2017 | $26,612,000 | -1.2% | 2,087,224 | +20.8% | 0.63% | +19.3% |
| Q3 2017 | $26,922,000 | +174.9% | 1,727,997 | +147.5% | 0.53% | +100.4% |
| Q2 2017 | $9,795,000 | -10.7% | 698,159 | +40.0% | 0.26% | -4.0% |
| Q1 2017 | $10,967,000 | – | 498,714 | – | 0.28% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 2,697,829 | $20,045,000 | 88.84% |
| TRV GP III, LLC | 3,048,780 | $22,652,000 | 4.30% |
| Logos Global Management LP | 2,000,000 | $14,860,000 | 1.07% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,559 | $1,550,000 | 0.88% |
| PFM Health Sciences, LP | 3,848,822 | $28,597,000 | 0.84% |
| Yorktown Management & Research Co Inc | 113,200 | $841,000 | 0.63% |
| Moloney Securities Asset Management, LLC | 282,250 | $2,097,000 | 0.38% |
| PATHWAY CAPITAL MANAGEMENT, LP | 84,763 | $630,000 | 0.30% |
| Sofinnova Investments, Inc. | 637,347 | $4,735,000 | 0.28% |
| Omega Fund Management, LLC | 275,513 | $2,047,000 | 0.23% |